CJC-1295 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Updated 2026-01-21. Numbers and descriptions here follow the published literature rather than marketing material.
Binding to GHRH receptors on pituitary somatotroph cells triggers cyclic AMP signaling and stimulates growth hormone synthesis and release. Because the peptide acts upstream of the pituitary, effects are mediated through endogenous growth hormone rather than direct receptor activation in peripheral tissues. Increases in insulin-like growth factor 1 are generally described as a downstream consequence. Most published human exposure data come from small early-stage studies, and the clinical significance of the pharmacokinetic profile remains incompletely characterized.
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Reported half-lives differ widely between the two variants and between species. Values for the albumin-binding form are usually expressed in days, while the unconjugated form is measured in minutes to a few hours. Sampling schedules, assay sensitivity, and route of administration all influence the numbers, which limits direct comparison across studies. Whether sustained receptor occupancy produces different downstream effects from pulsatile stimulation remains an open question in the published work. Claims about relative potency should therefore be read alongside the specific study design that produced them.
Lyophilised powder is the usual supplied form. The material is hygroscopic, so vials are typically equilibrated to room temperature before opening in order to prevent condensation on the contents. Long-term storage is generally described at minus twenty degrees Celsius or colder, protected from light and moisture. Repeated freeze-thaw cycles are avoided because they promote aggregation and loss of soluble material. A reconstituted solution is considerably less stable than the dry powder and is normally kept refrigerated for short periods only.
Identity and purity are assessed mainly by reversed-phase high-performance liquid chromatography combined with mass spectrometry. The chromatographic separation resolves the target peptide from truncation products and from species carrying oxidised residues, while mass measurement confirms the expected molecular mass. Because the two common variants differ by roughly 280 daltons, a mass determination distinguishes them unambiguously. Purity is often quoted as a percentage of total peak area, although that figure depends on the detection wavelength and the integration method applied.
| Property | Value | Notes |
|---|---|---|
| Physical form | Lyophilized white powder | Supplied as a freeze-dried solid for research use |
| Molecular weight | Approximately 3,647 Da (DAC form) | Lower for the variant lacking the albumin-binding moiety |
| Solubility | Soluble in water and aqueous buffer | Typically dissolved in sterile or bacteriostatic water |
| Typical storage temperature | −20 °C or below | Dry powder, desiccated and protected from light |
| Common analytical method | Reversed-phase HPLC with mass spectrometry | Used for purity estimation and identity confirmation |
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
The peptide backbone includes a D-alanine at position two, which resists cleavage by dipeptidyl peptidase IV, and several other substitutions that reduce degradation. Its molecular weight is roughly 3.4 kDa without the linker and about 3.6 kDa with it. The molecule is water soluble and is normally supplied as a lyophilized powder. Precise sequence and mass values depend on which variant is described, so technical documents usually state the exact form being referenced.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
Reports on this compound commonly follow serum growth hormone and insulin-like growth factor 1 across defined time windows. Protocols differ in sampling frequency, assay platform, and participant characteristics, which makes direct comparison between publications difficult. Some work focuses on pulsatile release patterns instead of average concentrations. Whether repeated exposure alters endogenous hormone rhythms over long periods remains an open question, and the formal literature is thinner than the volume of informal commentary implies.
Once in circulation, the peptide binds the growth hormone-releasing hormone receptor displayed on pituitary somatotroph cells. Receptor activation couples to Gs proteins, elevates intracellular cyclic AMP, and drives protein kinase A signaling inside the cell. That cascade increases discharge of growth hormone into the bloodstream. The analog therefore operates through a receptor pathway that already exists for the body's own releasing hormone, rather than through an engineered artificial target.
Clearance profiles diverge sharply between the two versions. The albumin-binding molecule stays in plasma for several days, whereas the unmodified analog is largely gone within about half an hour in reported work. Cleavage by dipeptidyl peptidase IV is a major contributor to the short life of the unmodified sequence. These gaps mean the two versions cannot be substituted for each other in study design or in reading results side by side.
Enteroglucagon is a proglucagon-derived peptide or enteroendocrine cells derived peptide in the small intestine. Preproglucagon undergoes post translational modification to release glucagon-like peptides (GLP-1 and GLP-2) and other molecules derived from L-cells of intestine. GLP-1 is derived from a class of intestinal hormones called incretin and the molecule exists in two forms GLP-1(7-37) and GLP-1(7-36) amide. GLP-1 form of incretin starts circulating in response to a high blood glucose level. Incretin effect is a negative feedback loop between glucose and insulin level, it promotes insulin release from beta cells of pancreas islet and suppresses glucagon when the glucose level is high. In vertebrate mammals, GLP-2 sequences are highly conversed in the intestine. The molecule functions as a part of adaptive response, such that contributes intestinal growth, proliferation effect, intestinal dilation (increases the mucosal blood flow) and reduces the chance of apoptosis.
=== Spanish === A localised edition of Edge was launched in Spain on 15 April 2006 by publisher Globus, which shares some staff from the On/Off editorial, a Globus magazine about DVD video and consumer technology, not in any way related to video games. It lacks some articles contained in the UK edition, such as the Virtua Fighter 5 story which was omitted from the corresponding Spanish edition. At the end of May 2009, a post in the official Edge Spanish forums made by the main administrator, stated that Globus was about to close its video game division, which meant the closure of the Spanish edition of Edge and NGamer. In October 2017, a new official Edge Spanish edition is released. A new number comes every two months.
== Spin-off characters == Leslian Marie Gold (レスリー星人マリー・ゴールド, Resurī Seijin Marī Gōrudo): An S.P.D. officer from Planet Leslie with the power to temporarily stop time who serves as Deka Gold (デカゴールド, Deka Gōrudo) and appears exclusively in the film Tokusou Sentai Dekaranger The Movie: Full Blast Action. While working undercover as a nightclub singer to investigate the Gas Drinkers' attack on Leslie, she encounters and falls in love with Ban. Marie Gold is portrayed by Chiharu Niiyama (新山 千春, Niiyama Chiharu) while her singing voice is provided by Sae (小枝). Kight Reidlich (カイト・レイドリッヒ, Kaito Reidorihhi): The corrupt chief of the Space Police's Galactic District Police Bureau who appears exclusively in the direct-to-video anniversary special Tokusou Sentai Dekaranger: 10 Years After. Two years prior, Kruger discovered Reidlich had been selling confidential information to the space mafia Qurlian Family (キルリアンファミリー, Kirurian Famirī), but the latter captured him and used his Master License's Mirage Dimension to pose as Kruger and frame him for killing the Qurlians and their Clementian hostage. However, the hostage's daughter Carrie witnessed everything and seeks the Dekarangers' help in stopping Reidlich in the present. After the Dekarangers expose him and rescue Kruger, Reidlich sacrifices his underlings, Assam Asimov and Mugi Grafton, to power his Neo Hyper Muscle Gear and overwhelm the Dekarangers, only to be deleted by them and Deka Master. Kight Reidlich is voiced by Rikiya Koyama (小山 力也, Koyama Rikiya).
=== Competition with other platforms === Although the size of its user base falls short of that of Facebook, Instagram, or YouTube, TikTok reached 1 billion active monthly users faster than any of them. Competition from TikTok prompted Instagram, which is owned by Facebook, to spend $120 million as of 2022 to entice more content creators to its Reels service, although engagement level remained low. Snapchat had likewise paid out $250 million in 2021 to its creators. Many platforms and services, including YouTube Shorts, began to imitate TikTok's format and recommendation page. Those changes caused a backlash from users of Instagram, Spotify, and Twitter. In March 2022, The Washington Post reported that Facebook's owner Meta Platforms paid Targeted Victory—a consulting firm backed by supporters of the US Republican Party—to coordinate lobbying and media campaigns against TikTok and portray it as "a danger to American children and society". Its efforts included asking local reporters to serve as "back channels" of anti-TikTok messages, writing opinion articles and letters to the editor, including one in the name of a concerned parent, amplifying stories about TikTok trends, such as "devious licks" and "Slap a Teacher", that actually originated on Facebook, and promoting Facebook's own corporate initiatives. Ties to Meta were not disclosed to the other parties involved. Targeted Victory said that it is "proud of the work". A Meta spokesperson said that all platforms, including TikTok, should face scrutiny.
=== Category:EC 1.1 (act on the CH-OH group of donors) === Category:EC 1.1.1 (with NAD+ or NADP+ as acceptor) Alcohol Dehydrogenase (NAD) EC 1.1.1.1 Alcohol Dehydrogenase (NADP) EC 1.1.1.2 Homoserine Dehydrogenase EC 1.1.1.3 Aminopropanol Oxidoreductase EC 1.1.1.4 Diacetyl Reductase EC 1.1.1.5 Glycerol Dehydrogenase EC 1.1.1.6 Propanediol-Phosphate Dehydrogenase EC 1.1.1.7 Glycerol-3-Phoshitiendopene Dehydrogenase (NAD+) EC 1.1.1.8 D-xylulose reductase EC 1.1.1.9 L-xylulose reductase EC 1.1.1.10 Lactate dehydrogenase EC 1.1.1.27 Malate dehydrogenase EC 1.1.1.37 Isocitrate dehydrogenase EC 1.1.1.42 HMG-CoA reductase EC 1.1.1.88 Category:EC 1.1.2 (with a cytochrome as acceptor) Category:EC 1.1.3 (with oxygen as acceptor) Glucose oxidase EC 1.1.3.4 L-Gulonolactone oxidase EC 1.1.3.8 Thiamine oxidase EC 1.1.3.23 Xanthine oxidase EC 1.1.3.32 Category:EC 1.1.4 (with a disulfide as acceptor) Category:EC 1.1.5 (with a quinone or similar compound as acceptor) Category:EC 1.1.99 (with other acceptors)
Sources: en.wikipedia.org
La Resistencia (The Resistance) is a right-wing decentralized group that opposes the Castillo Administration. The group has been behind threats of harassment, verbal assaults, and physical attacks on citizens and government officials. La Resistencia has accused their opponents of being terrorists and Senderistas. Following repeated threats against the former supreme prosecutor Avelino Guillén and the journalist Jaime Chincha, the Ministry of the Interior has ordered an investigation into the alleged criminal organization. On 7 October 2021, approximately ten members of La Resistencia assaulted a car which had journalists inside. The car had stopped due to a red light, which the group took advantage of by repeatedly hitting the car's windows and insulting its passengers. The journalists managed to escape, but the car was battered. On 18 October 2021, members of La Resistencia interrupted the initial book sale of "Imagine a better Peru... and let's make it happen." by former President Francisco Sagasti and blocked the doorways as to prevent people from leaving. There were shouts against Sagasti, decrying him as a "murderer" and a "terrorist." Previously, Sagasti had gotten backlash from proponents that there was electoral fraud in the 2021 Peruvian general election, due to him repeatedly denying that fraud took place and handing the presidency to Castillo. On 8 November 2021, the Interior Ministry claimed that groups consisting of ex-military and ex-police personnel are appearing, many of whom being veterans of the war against the Shining Path.
=== By spot nature === Apart from analytical methods, researchers would isolate core or rim ages for analysis. Normally, core ages would be used as crystallization age as they are first generated and least disturbed part in zircon grains. On the other hand, rim ages can be used to track peak metamorphism as they are first in contact with certain temperature and pressure condition. Researchers may utilize these different spot natures to reconstruct the geological history of a basin.
The panel noted the large number of failures to replicate excess heat and the greater inconsistency of reports of nuclear reaction byproducts expected by established conjecture. Nuclear fusion of the type postulated would be inconsistent with current understanding and, if verified, would require established conjecture, perhaps even theory itself, to be extended in an unexpected way. The panel was against special funding for cold fusion research, but supported modest funding of "focused experiments within the general funding system". Cold fusion supporters continued to argue that the evidence for excess heat was strong, and in September 1990 the National Cold Fusion Institute listed 92 groups of researchers from 10 countries that had reported corroborating evidence of excess heat, but they refused to provide any evidence of their own arguing that it could endanger their patents. However, no further DOE nor NSF funding resulted from the panel's recommendation. By this point, academic consensus had moved decidedly toward labeling cold fusion as a kind of "pathological science". In March 1990, Michael H. Salamon, a physicist from the University of Utah, and nine co-authors reported negative results. University faculty were then "stunned" when a lawyer representing Pons and Fleischmann demanded the Salamon paper be retracted under threat of a lawsuit. The lawyer later apologized; Fleischmann defended the threat as a legitimate reaction to alleged bias displayed by cold-fusion critics.
==== Re-release in Japan ==== Darbar was re-released as Dalbar Revenge, in Japan's theatre chain MKC Plex on 16 July 2021, and ran with a full house for a week. The film was supposed to be screened until 21 July but its run was extended to the end of July. According to some reports, it ran until August in some cities. According to Sify: Multiple shows are being added for [Darbar] in Japan. Huge demand for tickets there. Distributors are very happy with the profits ... According to reports, the movie has created quite a rage among fans. This is likely to be screened in more cities such as Kyoto, Nagoya, and Niigata, among others. According to media reports, Darbar grossed ¥230 million in Japan. The film earned approximately ₹15 crore. Darbar is the second-highest-grossing film for Rajinikanth in Japan after Muthu and fourth-highest grossing Indian film in Japan.
Sources: en.wikipedia.org
The two share the same 29-amino-acid backbone. CJC-1295 carries an additional albumin-binding moiety that markedly extends its residence time in circulation, while the form without that moiety clears faster. Literature sometimes applies the name loosely to either variant.
It has not been approved by major regulatory agencies for any therapeutic indication. Material sold under this name is typically distributed for laboratory research only. Clinical use is not supported by large controlled trials.
Early human studies of the albumin-binding form reported circulation half-lives on the order of several days. The value depends on assay method and study design. Estimates for the form without the binding moiety are considerably shorter.
Chromatography reports how much material elutes as a single peak but does not confirm what that material is. Mass spectrometry supplies the molecular mass, which is characteristic of a given sequence and its modifications. Together the two methods support both a purity figure and an identity claim.